Clinical Trial Update: Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety and immunogenicity of a norovirus GI.1/GII.4 bivalent VLP vaccine in older adults; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus

Drugs mentioned

• Norovirus GI.1/GII.4 bivalent virus-like particle vaccine (Norovirus GI.1/GII.4 virus-like particle vaccine)

Snippet

Sponsor: Takeda | Conditions: Norovirus | Phase 2 | Status: COMPLETED | Results posted: 2020-05-18